# Mentoring Patient Oriented Research in Innovative Imaging and High-dimensional Data Approaches to Improve Outcomes in Cardiac Amyloidosis

> **NIH NIH K24** · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $123,785

## Abstract

Project Summary/Abstract
Dr Sharmila Dorbala is an Associate Professor of Radiology at Harvard Medical School and a physician/scientist
at Brigham and Women's Hospital (BWH). She has devoted her career to patient-oriented research focusing on
cardiac amyloidosis. She contributed independently to the field of cardiac amyloidosis through a succession of
substantive studies utilizing molecular imaging to phenotype cardiac amyloidosis in order to diagnose and
manage this condition. Her research program is impactful, both directly and through effective mentoring of the
next generation of amyloidosis investigators. Dr. Dorbala has successfully mentored 26 pre- and post-doctoral
trainees in patient- oriented research projects. She is currently PI of two active NIH R01 grants and also has
funding from AHA and foundation/industrial sources. Her program provides a unique opportunity for POR due
to the intersection of resources from programs in clinical investigation at the Harvard School of Public Health
and the BWH cardiovascular imaging T32 program. Her mentees have presented their work nationally and
internationally, published papers, and won research awards and pilot grants.
The new research aims proposed in this award lay the foundation for adjunct interventions to enhance
transthyretin cardiac amyloidosis (ATTR-CA) therapies and novel image-based personalized strategies to predict
treatment failure. She will assess (1) sonoporation, a therapeutic ultrasound technique to increase myocardial
perfusion and, consequently, improve delivery of antifibril drugs; (2) shotgun metagenomic sequencing of the
gut microbiome to inform development of nutrition-based adjunct therapies; (3) radiomics of 99mTc-
pyrophosphate SPECT/CT to assess treatment response, and (4) machine learning based CT-derived sarcopenia
metric to predict survival. This research has important clinical implications. Currently approved TTR
stabilizing/silencing drugs, though lifesaving for most, are not effective in about 30% of patients. Moreover,
while these therapies improve clinical outcomes, they do not treat amyloid fibril. Fibril-targeted therapies have
been unsuccessful to date, probably because of poor interstitial drug delivery due to the presence of fibril. The
results of the proposed mentoring and research activities of this K24 project are likely to not only substantially
improve outcomes and alleviate HF symptoms in these gravely ill patients, but also transform her patient-
oriented research program into a formal individualized program of mentoring with a focus on preventing heart
failure from amyloidosis.

## Key facts

- **NIH application ID:** 10844636
- **Project number:** 5K24HL157648-04
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Sharmila Dorbala
- **Activity code:** K24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $123,785
- **Award type:** 5
- **Project period:** 2021-05-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10844636

## Citation

> US National Institutes of Health, RePORTER application 10844636, Mentoring Patient Oriented Research in Innovative Imaging and High-dimensional Data Approaches to Improve Outcomes in Cardiac Amyloidosis (5K24HL157648-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10844636. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*